Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
Status:
Completed
Trial end date:
2018-09-06
Target enrollment:
Participant gender:
Summary
The purpose of this extension study was to assess the safety and efficacy of the new
formulation of brolucizumab 6 mg ophthalmic solution when given to the same patients who
received brolucizumab in the core trial CRTH258A2301 (also known as CRTH258-C002). The
medical condition treated in the core and extension trials was neo-vascular age-related
macular degeneration (nAMD).